89Zr-trastuzumab-PET gauges treatment response in gastric cancer

04/24/2013 | HealthImaging.com

PET imaging with 89Zr-trastuzumab is effective in monitoring treatment response in animals with human epidermal growth factor receptor 2-positive stomach cancer being treated with afatinib, according to findings from a study published in The Journal of Nuclear Medicine. Researchers said 89Zr-trastuzumab-PET performed better than 18F-FDG-PET in determining drug uptake. There is a need for human studies to validate the efficacy of the method in monitoring treatment response, researchers added.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY